Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
(R)-11-Hydroxyaporphine (2) and (R)-11-hydroxy-10-methylaporphine (3) were synthesized from natural morphine by using new, short, and efficient synthetic sequences. The dopaminergic and serotonergic effects of 2 and 3 were evaluated by use of in vitro and in vivo test systems. The results indicate that 3 is a potent, selective, and efficacious
5-HT1A
receptor agonist. In contrast, 2 is a partial
5-HT1A
receptor agonist of low potency which has affinity also for central D1 and D2A receptors. The differences in pharmacological profiles were rationalized by modeling of ligand-receptor interactions using homology-based receptor models of the
5-HT1A
and D2A receptor binding site. The selective and pronounced serotonergic effects of 3 appear to be due to the
C10
-methyl group, which is accommodated by a lipophilic pocket in the
5-HT1A
receptor. In contrast, the
C10
-methyl group of 3 is not accommodated by the binding site model of the D2A receptor.
...
PMID:(R)-11-hydroxy- and (R)-11-hydroxy-10-methylaporphine: synthesis, pharmacology, and modeling of D2A and 5-HT1A receptor interactions. 786 13
Derivatives of the selective serotonin
5-HT1A
receptor agonist (R)-11-hydroxy-10-methylaporphine (2) having various substituents in the
C10
-position or at the nitrogen have been synthesized from natural morphine or 6-O-acetylcodeine, respectively. The
C10
-substituents were introduced using efficient Stille or Suzuki cross-coupling reactions. The compounds were evaluated for their affinities to
5-HT1A
and dopamine (DA) D1 and D2A receptors in vitro. All compounds tested displayed low (micromolar) affinities to D1 and D2A receptors. In addition, changes in steric bulk and/or electronic properties of the
C10
-substituent as compared to a
C10
-methyl group, as well as substitution of the N-methyl group for a hydrogen or a larger N-alkyl group, produced a marked decrease in the affinities to
5-HT1A
receptors. Selected compounds that displayed moderate to high affinities to
5-HT1A
receptors were evaluated for their ability to stimulate
5-HT1A
receptors in vivo. The evaluated compounds behaved as agonists at
5-HT1A
receptors, except for the N-propyl analogue of 2, (R)-11-hydroxy-10-methyl-N-propylnoraporphine (23), which displayed weak DA receptor agonism at the doses tested. Hence, the substitution pattern of 2 (a
C10
-methyl, a C11-hydroxy, and an N-methyl group) appears to be optimal for potent interaction of 10,11-disubstituted (R)-aporphines with
5-HT1A
receptors. Modeling of ligand-
5-HT1A
receptor interactions was performed in an attempt to rationalize the observed affinity data. The binding site model suggests the presence of a "methyl pocket" in the
5-HT1A
receptor binding ste. The C11-methoxy-substituted aporphines appear to have a different binding mode compared to 2, implying a different accessibility of these compounds to the "methyl pocket".
...
PMID:10-substituted 11-oxygenated (R)-aporphines: synthesis, pharmacology, and modeling of 5-HT1A receptor interactions. 878 47